We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study.
- Authors
Birabaharan, Morgan; Hill, Eddie; Begur, Maedha; Kaelber, David C; Martin, Thomas C S; Mehta, Sanjay R
- Abstract
Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
- Subjects
THERAPEUTIC use of monoclonal antibodies; RELATIVE medical risk; COVID-19; CONFIDENCE intervals; CARDIOVASCULAR diseases; RETROSPECTIVE studies; PRE-exposure prophylaxis; RISK assessment; DESCRIPTIVE statistics; DATA analysis software
- Publication
Clinical Infectious Diseases, 2023, Vol 76, Issue 8, p1500
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciac894